A new prediction tool may help assess the risk of preterm birth (before 37 weeks of gestation) in women affected by intrahepatic cholestasis of…
News
FATTY LIVER DISEASE
NewsBelapectin shows signs of benefit in MASH Phase 2b clinical trial
Belapectin, Galectin Therapeutics’ investigational therapy, significantly reduced the development of new enlarged blood vessels in the esophagus among people with metabolic dysfunction-associated steatohepatitis (MASH),…
ALAGILLE SYNDROME
NewsItching at night tied to sleep problems for Alagille kids – and their caregivers
Due to itching at nighttime, children with Alagille syndrome often experience substantial problems getting a good night’s sleep, leading to poor rest not only…
GlaxoSmithKline (GSK) has submitted an application to Health Canada seeking approval of its chronic hepatitis B therapy bepirovirsen for treating adults with the…
Low blood levels of vitamin B6 — found in certain foods and essential for metabolism and immune function in the body — can increase the…
Rare genetic liver conditions like progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome pose a substantial financial and quality-of-life burden on families, a study…
FATTY LIVER DISEASE
NewsMadrigal Pharmaceuticals expands MASH pipeline with genetic treatment
Madrigal Pharmaceuticals has secured worldwide rights to develop ARO-PNPLA3, an experimental treatment created by Arrowhead Pharmaceuticals for people with metabolic dysfunction-associated steatohepatitis (MASH),…
BILIARY ATRESIA
NewsCMV marker in bile duct cells tied to worse biliary atresia outcomes
Children with biliary atresia who had evidence of active cytomegalovirus (CMV) infection involving bile duct cells in the liver had signs of more severe…
HEPATITIS
NewsAdvocates push for testing during Hepatitis Awareness Month
May is Hepatitis Awareness Month, and advocates are working to spread the word about viral hepatitis — a group of infections that cause liver…
Twice-daily treatment with volixibat, Mirum Pharmaceuticals’ oral investigational therapy for primary sclerosing cholangitis (PSC) significantly outperformed a placebo in reducing moderate to severe…
Recent Posts
- Putting out the fires of inflammation in liver disease
- Change is good, but in life with MASH, it’s important to start small
- It turns out that having great friends is good for my health
- With Alagille syndrome, summer fun comes with a summer caution
- Gene therapy shows early promise for fatal childhood liver disease